Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.
Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.
Celecoxib, in combination with tramadol, is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
- Associated Therapies
- -
A Multiple Dose Study of LY3023703 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT01849055
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States
Phase III Study of CG100649 in Osteoarthritis Patients
- Conditions
- Interventions
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- CrystalGenomics, Inc.
- Target Recruit Count
- 362
- Registration Number
- NCT01765296
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Chungnam National University Hospital, Daejeon, Korea, Republic of
🇰🇷NHIC Ilsan Hospital, Goyang-si, Korea, Republic of
CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen
- Conditions
- Interventions
- First Posted Date
- 2013-01-08
- Last Posted Date
- 2013-01-08
- Lead Sponsor
- Hospital Universitario Pedro Ernesto
- Target Recruit Count
- 22
- Registration Number
- NCT01762891
A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 27
- Registration Number
- NCT01729923
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 21
- Registration Number
- NCT01705106
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer
- First Posted Date
- 2012-09-27
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Maastricht University Medical Center
- Registration Number
- NCT01695226
- Locations
- 🇳🇱
University Hospital Maastricht, Maastricht, Limburg, Netherlands
A Single Dose Study of LY3023703 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2012-07-03
- Last Posted Date
- 2018-08-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT01632579
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States
A Multiple-dose Study of LY3031207 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2012-07-03
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 39
- Registration Number
- NCT01632566
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Honolulu, Hawaii, United States
Celecoxib for Primary Prophylaxis of Combat-Related Heterotopic Ossification
- First Posted Date
- 2012-06-29
- Last Posted Date
- 2012-07-03
- Lead Sponsor
- Walter Reed National Military Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT01631669
- Locations
- 🇩🇪
Landstuhl Military Medical Center, Landstuhl, Germany
🇺🇸Walter Reen National Military Medical Center Bethesda, Bethesda, Maryland, United States
Statins and Selective Cyclooxygenase-2 Receptor Inhibitors in Blunt Chest Trauma
- Conditions
- Interventions
- First Posted Date
- 2012-06-20
- Last Posted Date
- 2012-06-20
- Lead Sponsor
- Tel-Aviv Sourasky Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT01623921
- Locations
- 🇮🇱
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.